Saturday 17 October 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3% and free cash flow grew 7.91%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.
3.38
0.22
−6.11%
Follow ANTX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 35.85 | 2.90 | 17.70 | 13.72 | 7.87 | 8.43 | 6.87 |
Net Debt/EBITDA |
— | 1.08 | 0.56 | 2.72 | 2.24 | 1.48 | 1.39 | 1.48 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.43 | 0.37 | 0.73 | 0.78 | 0.82 | 0.96 | 0.85 |
Capex/Depreciation |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 43.91% | 111.67% | 82.85% | (178.38%) | (58.83%) | (49.69%) | (52.14%) | |
| — | (201.19%) | (293.62%) | (80.68%) | (50.96%) | (53.65%) | (44.47%) | (45.67%) | |
ROIC |
— | 0.00% | 0.00% | (402.14%) | 0.00% | (250.04%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (103.48%) | (525.55%) | (49.48%) | (46.78%) | (67.10%) | (67.51%) | (68.68%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.13) | (2.09) | (7.76) | (2.18) | (2.26) | (1.65) | (0.99) |
Cash per Share |
— | 0.30 | 1.58 | 22.20 | 6.26 | 4.55 | 2.80 | 1.92 |
Shareholders Equity per Share |
— | 0.26 | 1.07 | 23.47 | 6.22 | 5.28 | 2.74 | 1.76 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.26 | 1.07 | 23.47 | 6.22 | 5.28 | 2.74 | 1.76 |
Free Cash Flow |
— | (2.49) | (5.36) | (20.48) | (33.46) | (53.29) | (49.26) | (29.83) |
Working Capital |
— | 5.54 | 2.78 | 56.71 | 91.44 | 96.46 | 76.02 | 51.22 |
Net Current Asset Value |
— | 4.81 | 2.75 | 56.70 | 91.43 | 96.46 | 76.02 | 51.05 |
| Other line items | ||||||||
Quick Ratio |
— | 35.21 | 2.79 | 17.25 | 13.37 | 7.64 | 8.17 | 6.65 |
Depreciation/Fixed assets |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
— | (23.88%) | (78.64%) | (17.00%) | (17.48%) | (22.97%) | (29.77%) | (26.86%) |
Accounts Payable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.13) | (2.09) | (7.76) | (2.18) | (2.26) | (1.65) | (0.99) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | — | — | 0.60 | 1.59 | 2.40 | 3.00 | 3.17 |
Average Assets |
— | 2.85 | 4.97 | 34.78 | 83.94 | 120.65 | 115.42 | 77.02 |
Average Common Equity |
— | (13.06) | (13.06) | (33.86) | 23.98 | 110.04 | 103.28 | 67.45 |
Columns are period end dates